Notice of Pre-AIA or AIA Status
The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA .
Status of Claims
Claims 1-2, 45, 49, 51, 55, 70, 78, 80, 102, 105, 137-138, 141, 144, 147, 152, 153, 148, and 160-161 are pending in the instant application.
Claims 3-44, 46-48, 50, 52-54, 56-69, 71-77, 79, 81-101, 103-104, 106-136, 139-140, 142-143, 145-146, 148-151, 154-157, 159, and 162-164 have been canceled.
Claims 153, 158, and 161 stand withdrawn.
Information Disclosure Statement
The Information Disclosure Statement filed January 14th, 2026 has been fully considered by the examiner, except where marked with a strikethrough.
Withdrawn Rejections/Objections
Applicant’s amendment is sufficient to overcome the objection to Claim 137. This objection is hereby withdrawn.
Applicant’s amendment is sufficient to overcome the rejection of Claims 1, 2, 45, 49, 51, 55, 70, 78, 80, 102, 105, 138, 141, 144, 147, 152, and 160 under 35 U.S.C. 112(a). This rejection is hereby withdrawn.
Applicant’s amendment is sufficient to overcome the rejections of Claims 78, 105, and 160 under 35 U.S.C. 112(b). These rejections are hereby withdrawn.
Applicant’s amendment is sufficient to overcome the rejections of Claims 1-2, 45, 49, 51, 55, 70, 78, 80, 138, 141, and 144 under 35 U.S.C. 102(a)(1). These rejections are hereby withdrawn.
The following rejections are necessitated by amendment:
Claim Rejections - 35 USC § 102
The text of those sections of Title 35, U.S. Code not included in this action can be found in a prior Office action.
Claims 1-2, 49, 51, 70, 78, 137-138, 141, and 144 are rejected under 35 U.S.C. 102(a)(1) as being anticipated by CAS Registry File 76167-43-6 (entered into STN November 16th, 1984; hereinafter referred to as CAS Registry File 1).
CAS Registry File 1 teaches a compound having the following structure:
PNG
media_image1.png
138
390
media_image1.png
Greyscale
This compound reads on a compound of Formula (I) as recited at instant Claim 1 when the variables are defined as follows:
X is CR3, wherein R3 is hydrogen.
Y and Z are each N.
T is
PNG
media_image2.png
72
83
media_image2.png
Greyscale
, wherein m is 0.
R1 and R2 are each hydrogen.
R4 is unsubstituted alkyl, wherein alkyl is methyl.
R6 and R7 are each hydrogen.
s is 0.
Regarding Claim 2, this compound reads on a compound of formula (I-gg).
Claims 1, 51, 55, 70, 137-138, 141, and 144 are rejected under 35 U.S.C. 102(a)(1) as being anticipated by WO2003/082855 (Machine translation provided; hereinafter referred to as WO ‘855).
At Page 57, WO ‘855 teaches compounds of the formula:
PNG
media_image3.png
110
175
media_image3.png
Greyscale
At Page 57, entry 107, WO’855 defines R1 as
PNG
media_image4.png
52
153
media_image4.png
Greyscale
and R7a as
PNG
media_image5.png
50
99
media_image5.png
Greyscale
.
For clarity, the full structure of this compound is:
PNG
media_image6.png
326
469
media_image6.png
Greyscale
This structure reads on a compound of formula (I) as recited at instant Claim 1 when the variables are defined as follows:
X is CR3, wherein R3 is cyano.
Y and Z are each N.
T is
PNG
media_image2.png
72
83
media_image2.png
Greyscale
, wherein m is 0.
R1 is N(RA)2, wherein one RA is hydrogen, and the other is unsubstituted alkyl, wherein alkyl is pentyl.
R2 is hydrogen.
R4 is unsubstituted alkyl, wherein alkyl is methyl.
R6 and R7 are each hydrogen.
s is 0.
Claims 1-2, 45, 51, 78, 137-138, 141, and 144 are rejected under 35 U.S.C. 102(a)(1) as being anticipated by CAS Registry File 1309115-40-9 (entered into STN June 13th, 2011; hereinafter referred to as CAS Registry File 2).
CAS Registry File 2 teaches the following compound:
PNG
media_image7.png
221
478
media_image7.png
Greyscale
This compound reads on a compound of formula (I) as recited at instant Claim 1 when the variables are defined as follows:
X and Y are each N.
T is
PNG
media_image2.png
72
83
media_image2.png
Greyscale
, wherein m is 0.
Z is CR3, wherein R3 is hydrogen.
R1 is hydrogen.
R2 is substituted alkyl, wherein alkyl is ethyl, substituted with N(Rbb)2, as specified at Page 27, Paragraph 0048 of the instant specification, wherein each Rbb is hydrogen, as specified at Page 28, Paragraph 0048 of the instant specification.
R4 is unsubstituted alkyl, wherein alkyl is methyl.
R6 and R7 are each hydrogen.
s is 0.
Regarding Claim 2, this compound reads on a compound of formula (I-a).
Claims 1-2, 51, 78, 137-138, 141, and 144 are rejected under 35 U.S.C. 102(a)(1) as being anticipated CAS Registry File 2286943-74-4 (entered into STN March 15th, 2019; cited on Applicant’s Information Disclosure Statement filed January 14th, 2026; hereinafter referred to as CAS Registry File 3).
CAS Registry File 3 teaches the following compound:
PNG
media_image8.png
241
446
media_image8.png
Greyscale
This compound reads on a compound of formula (I) as recited at Claim 1 when the variables are defined as follows:
X and Z are each N.
Y is CR3, wherein R3 is hydrogen.
T is
PNG
media_image2.png
72
83
media_image2.png
Greyscale
, wherein m is 0.
R1 is hydrogen.
R2 is -N(RA)2, wherein each RA is hydrogen.
R4 is unsubstituted alkyl, wherein alkyl is methyl.
R6 and R7 are each hydrogen.
s is 0.
Regarding Claim 2, this compound reads on a compound of formula (I-f).
Allowable Subject Matter
Claims 80, 102, 105, 152, and 160 are objected to as being dependent upon a rejected base claim, but would be allowable if rewritten in independent form including all of the limitations of the base claim and any intervening claims.
Conclusion
Claims 1-2, 45, 49, 51, 55, 70, 78, 137-138, 141, and 144 are rejected.
Claims 80, 102, 105, 152, and 160 are objected to.
No claim is allowed.
Applicant's amendment necessitated the new ground(s) of rejection presented in this Office action. Accordingly, THIS ACTION IS MADE FINAL. See MPEP § 706.07(a). Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a).
A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any nonprovisional extension fee (37 CFR 1.17(a)) pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of this final action.
Any inquiry concerning this communication or earlier communications from the examiner should be directed to DANIEL JOHN BURKETT whose telephone number is (703)756-5390. The examiner can normally be reached Monday - Friday.
Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice.
If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Jeffrey Murray can be reached at (571) 272-9023. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.
Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.
/D.J.B./Examiner, Art Unit 1624
/JEFFREY H MURRAY/Supervisory Patent Examiner, Art Unit 1624